Life-saving properties of beta blockers extend to more patients

October 28, 2002

DALLAS, Oct. 29 - Beta blocker drugs have now been shown to lengthen the lives of people at risk of sudden death due to irregular heart beats, according to a study published in today's rapid access issue of Circulation: Journal of the American Heart Association.

The protective mechanism of beta blockers is unclear, says lead author Kristin E. Ellison, M.D., of Brown Medical School in Providence, R.I. It is likely due to the combined effects of beta blockers improving blood flow and reducing blood pressure, heart rate, and rhythm disturbances.

Sudden cardiac death occurs when the heart stops abruptly (cardiac arrest). It kills about 250,000 American lives every year, according to the American Heart Association. Most cardiac arrests that lead to sudden death occur when the electrical impulses in a diseased heart become rapid, called ventricular tachycardia, or chaotic, called ventricular fibrillation.

Beta blockers have been shown to reduce the risk of death by 25 percent to 40 percent in patients who've had a recent heart attack and to reduce sudden cardiac death up to 50 percent in patients with a recent heart attack, researchers say. However, until now, it hadn't been known if beta blockers have a similar positive effect on patients three or more years after a heart attack or in a group at high risk for sudden death due to heart rhythm disturbances.

Ellison and colleagues from the Multicenter UnSustained Tachycardia Trial (MUSTT) analyzed data from this prospective, randomized, controlled trial to evaluate the impact of beta blockers on the overall death rate and on death from an arrhythmia (abnormal heartbeat) or the need for resuscitation from cardiac arrest.

MUSTT was designed to test the effectiveness of electrophysiologic (EP) studies - invasive procedures used to record electrical activity from the heart or to administer medications while monitoring their effects. EP studies can test how well antiarrhythmic therapy reduces sudden death and death from other causes in patients with coronary heart disease. The enrollees had a prior heart attack, an ejection fraction (EF) - a measure of the heart's pumping strength - less than or equal to 40 percent, and nonsustained ventricular tachycardia during EP testing. On average, they were enrolled 39 weeks after their most recent heart attack.

The group was divided into those with sustained tachycardia and those without it. The first group was randomly assigned in equal proportions to antiarrhythmic therapy or no therapy, with a small number receiving implantable cardioverter defibrillators (ICDs) if they didn't respond to antiarrhythmic drugs. The group without sustained tachycardia received no antiarrhythmic therapy and was recorded in a registry.

The analysis reviewed 2,096 patients (702 randomized and 1,394 registry patients) enrolled at 85 sites in the United States and Canada between November 1990 and October 1996. Of them, 799 patients received beta blockers - 314 in the randomized group and 485 in the registry group. Of patients who didn't receive a beta blocker, 388 were in the randomized group and 909 were in the registry. Researchers found that death rates for beta blocker patients were 16 percent at two years and 34 percent at five years, significantly lower than the death rates of 27 percent at two years and 50 percent at five year for patients not receiving beta blockers.

The life-saving properties of beta blockers were consistent across the spectrum of study patients, such as those with and without inducible tachycardia. Patients with ICDs were the exception.

In contrast to the positive effect that beta blockers had on the overall death rate, the drugs didn't significantly reduce arrhythmic death or cardiac arrest, the study's primary end points. However, the authors note, "there was a trend toward fewer arrhythmic events and improved survival in those treated with antiarrhythmic drugs in combination with beta blocker therapy compared with antiarrhythmic therapy alone."

This trend was not seen in patients with ICDs, likely reflecting the "significant impact of ICD therapy on sudden cardiac death and the difficulty in further decreasing event rates," they add.

The authors note that patients treated with beta blockers were younger, had higher EF rates, higher rates of recent angina, and more recent heart attacks.

A limitation of the study was the inability to randomize the use of beta blockers because the administration of this therapy was left to the discretion of the referring physicians. Another drawback was that the effects of beta blockers in patients who received antiarrhythmic drugs may be obscured because several of these drugs possess some beta blocker activity.

Even so, the significant decrease in the overall death rate of these high-risk patients taking beta blockers and who hadn't had a recent heart attack combined with previous similar evidence lead the authors' to conclude "it is appropriate to prescribe these drugs in patients with the characteristics of those enrolled in the MUSTT trial."
-end-
Co-authors are Gail E. Hafley; Kathleen Hickey; Joyce Kellen; James Coromilas, M.D.; Kenneth M. Stein, M.D.; Kerry L. Lee, Ph.D.; and Alfred E. Buxton, M.D., for the MUSTT investigators.

The National Heart, Lung and Blood Institute helped fund the study.

NR02-1192 (Circ/Ellison)

CONTACT: For journal copies only,
please call: (214) 706-1396
For other information, call:
Carole Bullock: (214) 706-1279
Bridgette McNeill: (214) 706-1135

American Heart Association

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.